司帕沙星与洛美沙星随机对照治疗急性细菌性感染多中心研究

采用国产司帕沙星（ｓｐａｒｆｌｏｘｃｃｉｎ）与洛美沙星（ｌｏｍｅｆｌｏｘａｃｉｎ）随机对照治疗呼吸道、泌尿道、皮肤软组织急细菌性感染及淋球菌笥为。共２０２例，试验组１０２例，对照组１００例，司帕沙星２００ｍｇ，每日１次，洛美沙星２００ｍｇ、３００ｍｇ每日２次，疗程５～１４天，两组的痊愈率与有效率分别为７９．４１％与９１。．１８％及６８．００％与８４．００％。两组细菌阳性率、清除率及阴转率分别为９５

Multicenter evaluation on efficacy and safety of sparfloxacin versus lomefloxacin in the treatment of acute bacterial infections

An open, multicentre, randomised study was carried out to assess the efficacy and safety of sparfloxacin versus lomefloxacin in the treatment of bacterial infections of hospitalized patients. 202 patients with respiratory tract infection, urinary tract infection and skin structure infections were enrolled. 102 patients received sparfloxacin 200mg once daily and 100 patients received lomefloxacin 200mg twice daily for 5~14 days. The efficacy rate were 91.18% and 84% respectively in two groups, with no statistically singificant difference ( P = 0.1386 ). The bacteriological eradication rates were 93% and 86.45% respectively ( P =0.2326). The adverse reactions were five (4.85%) cases in sparfloxacin group and four (3.96%) cases in lomefloxacin group, most of them were nausea, vomiting. One patient had to withdraw from sparfloxacin group due to severe vomiting and nausea. There was no photosenstivity reaction. In conclusion, the results showed that sparfloxacin is well tolerated and as effictive as lomefloxacin but more convenicence.